Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

AI in Prostate Cancer Diagnosis and Treatment Gains Clinical Ground

An interview with Dr. David Albala examines how AI is reshaping prostate cancer diagnosis, imaging, risk stratification, and treatment decisions.

By Dr. Revathy Mohan V.R., MBBS · Oct 19, 2026 · 6 min read

Oncology·Nature

CT Fat Quality Metrics Track Nutritional Risk in Gastric Cancer

CT-based fat attenuation and density measurements were linked to prognostic nutritional index and albumin in 54 gastric cancer…

Oct 19, 2026

Oncology·bioRxiv

Colorectal Cancer Tumor Budding Signature Emerges Only at Single-Cell Resolution

A colorectal cancer preprint finds tumor-budding gene co-expression is strong in single-cell data but weak in bulk RNA-seq,…

Oct 19, 2026

Oncology·NICE

NICE backs inavolisib regimen for PIK3CA-mutated advanced breast cancer

NICE guidance covers inavolisib with palbociclib and fulvestrant for recurrent ER-positive, HER2-negative, PIK3CA-mutated advanced breast cancer.

Oct 19, 2026

Oncology·Nat Rev Onc

Pemigatinib FIGHT-302 Raises Trial-Design Questions in Cholangiocarcinoma

Pemigatinib improved progression-free survival and response in FGFR2-rearranged cholangiocarcinoma, but FIGHT-302 exposed trial-design and regulatory limits.

Oct 19, 2026

Oncology·Nat Rev Onc

ADC and ICI Toxicity Framework Aims to Standardize Overlapping Adverse Events

Nature Reviews Clinical Oncology proposes a unified framework for managing overlapping toxicities from antibody–drug conjugates and checkpoint inhibitors.

Oct 19, 2026

Oncology·Nat Rev Onc

Multiple Myeloma De-escalation Strategies Gain Clinical Ground

A Nature Reviews Clinical Oncology review outlines how multiple myeloma treatment may be safely reduced through MRD-guided, fixed-duration,…

Oct 19, 2026

Oncology·Nat Rev Onc

Liquid biopsy biomarkers sharpen immuno-oncology monitoring in blood

Nature review outlines how liquid biopsy biomarkers in blood may track immune response, resistance, and minimal residual disease…

Oct 19, 2026

Oncology·Nat Rev Onc

COMPETE Trial: 177Lu-edotreotide Tops Everolimus in GEP NETs

Phase III COMPETE data show 177Lu-edotreotide monotherapy outperformed everolimus in advanced somatostatin receptor-positive GEP NETs.

Oct 19, 2026

Oncology·Front Immunol

Thalidomide 100 mg Cuts Camrelizumab RCCEP More Than 50 mg in Phase II Trial

A multicenter phase II trial tested thalidomide 50 mg versus 100 mg daily to prevent camrelizumab-related RCCEP in…

Oct 19, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.